Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 4/20 | 0.39 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136446 | 1.00 | LMNA (0.50) | LMNAGAATSHRKMT2APPARA | |
| SCHEMBL6136460 | 0.86 | LMNA (0.56) | LMNAGAATSHRKMT2APPARA | |
| SCHEMBL6136457 | 0.86 | LMNA (0.56) | LMNAGAATSHRKMT2APPARA | |
| SCHEMBL4414750 | 0.75 | POLB (0.54) | KMT2AHPGD | |
| SCHEMBL4414752 | 0.75 | POLB (0.54) | KMT2AHPGD | |
| SCHEMBL4411585 | 0.75 | HPSE (0.56) | LMNAKMT2APPARGHPGD | |
| SCHEMBL4411588 | 0.75 | HPSE (0.56) | LMNAKMT2APPARGHPGD | |
| SCHEMBL24663712 | 0.74 | LMNA (0.52) | LMNAGAATSHRKMT2APPARA | |
| SCHEMBL4415149 | 0.73 | SMN1; SMN2 (0.44) | LMNAKMT2A | |
| SCHEMBL4415152 | 0.73 | SMN1; SMN2 (0.44) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | claimed |
| US-6767918-B2 | ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-07-27 | — | — | US | claimed |
| US-20030191119-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2003-10-09 | — | — | US | claimed |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-09-26 | — | — | US | claimed |
| US-6313152-B1 | ADMINISTERING N(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS FOR THERAPY OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2001-11-06 | — | — | US | claimed |
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6767918-B2 | ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-07-27 | — | — | US | disclosed |
| US-6642261-B2 | N-(phenylacetyl)alanine, isobutyl ester for example; prophylaxis and treatment of Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030191119-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2003-10-09 | — | — | US | disclosed |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-09-26 | — | — | US | disclosed |
| US-6333351-B1 | ENZYME INHIBITORS WITH CARRIERS | ATHENA NEUROSCIENCES, INC. | 2001-12-25 | — | — | US | disclosed |
| US-6313152-B1 | ADMINISTERING N(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS FOR THERAPY OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6117901-A | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use | ATHENA NEUROSCIENCES, INC. (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | LMNA 1921/4885GAA 33/4885TSHR 3457/4885 |
| US-20030191119-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | LMNA 1921/4885GAA 33/4885TSHR 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.